Biogen Litifilimab Shows Efficacy in 52-Week Lupus Study
Biogen announced 52-week results from the Phase 2 part of the AMETHYST Phase 2/3 study of litifilimab in patients with cutaneous lupus erythematosus (CLE). The updated results reinforce its potential as a first-in-class therapy.